Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant vs Ondansetron for PONV in Thoracic Surgery
NCT05881486Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of fosaprepitant in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Incidence of Postoperative Nausea and Vomiting at 24 hours. Status: unknown.
02
Drugs
fosaprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT05881486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881486.